Abstract: A treatment system for stimulating the vagus nerves is described, comprising the following elements: —a detection and control unit (20); —at least one detection probe (10d, 10g) connected to the detection and control unit and intended to be applied to at least one of the two vagus nerves of a patient; —means (24) provided in the detection and control unit for detecting a phenomenon of mass discharge of action potentials in at least one vagus nerve using the detection probe or detection probes; —stimulation probes (10d, 10g) for stimulating vagus nerves, and—means (24) provided in the detection and control unit that are capable, in response to the detection of a mass discharge, of applying predefined asymmetric stimulation signals to said stimulation probes capable of causing a depolarization and/or hyperpolarization of the vagus nerves and of blocking the conduction of the action potentials at least in the efferent direction.

Abstract: The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.

Abstract: The present invention relates to an aqueous solution for organ preservation, in particular for the myocardium, the solution comprising: 100 mM to 130 mM of Na+; 12 mM to 15 mM of K+; 0.25 mM to 1.3 mM of Ca++; 0.5 ?M to 1.5 ?M of cyclosporin A; and 0.5 ?M to 1.5 ?M of taxol, and it also relates to the joint use of cyclosporin A and taxol in a solution for in vitro preservation of an organ, in particular the myocardium.

Abstract: The method of characterizing an ultrasound lesion (T) in organic tissues, the lesion being made by applying high intensity focused ultrasound delivered by a probe having its emission surface presenting a shape that is toroidal, consists in: after a period of at least two days from the end of ultrasound application, acquiring at least one characterization image (Ic) of the organic tissues; detecting the presence of a contrast border (16) in the characterization image (Ic); and from the contrast border (16), determining the extent of the ultrasound lesion.

Abstract: The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with Rheumatoid Arthritis (RA). More specifically, the invention provides epitopes of PAD4, of BRAF, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of RA, in particular for the diagnosis of RA in CCP-negative subjects.

Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.

Abstract: The present invention relates to a transgenic animal mode system based on the development of transgenic mice bearing components of the human immune system. Specifically, the Invention relates to a Flk2 deficient Rag “?c” transgenic mouse and the engraftment of said mouse with human hematopoietic stem cells. The present invention further presides methods for increasing the numbers of functionally competent human dendritic cells is and the hematopoietic targets cells that they interact with in said transgenic mouse through the administration of Flk2L. The transgenic animal model system of the invention may be used for testing human vaccine candidates, for screening potential Immune adjuvants and for developing novel therapeutics.

Abstract: The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.

Abstract: Method of using one element chosen among a nucleic acid molecule, a fragment of the nucleic acid molecule and a variant of the nucleic acid molecule for the in vitro or ex vivo diagnosis of any type of somatic or ovarian cancers, wherein at least one of any of the above described elements is abnormally expressed in cancer cells of at least one type of the somatic or ovarian cancers, and wherein each type of somatic or ovarian cancer cells abnormally expresses at least one of the above described elements.

Abstract: This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.

Abstract: The present invention relates to a protein comprising or consisting of one of the following sequences: the sequence SEQ ID NO: 2 or SEQ ID NO: 4, or a fragment of said sequence represented by one of the sequences SEQ ID NO: 2q, q varying from 3 to 36, or the sequence SEQ ID NO: 185 to SEQ ID NO: 209. It also relates to a nucleotide sequence coding for said protein.

Abstract: The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active.

Abstract: The invention relates to a method for assessing the risk of a cardiovascular disease and/or for diagnosing dyslipidemia in a patient, said method comprising: a) isolating in a blood sample obtained from said patient the high density lipoprotein (HDL) fraction or a subfraction thereof; and b) measuring in said HDL fraction or subfraction thereof the concentration of one or more biomarkers selected from the group consisting of Sphingosine-1-Phosphate (S1P), sphingomyelin (SM) and Apolipoprotein A-I (apoA-1).

Abstract: Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed.